Agenda

 

 

SAN DIEGO, 28 November 2022 - 1 December 2022

Schedule

Create your personal agenda –check the favourite icon

Nov 2814:00
Conference pass

Workshop A [Room: Constellation A]

WVIC - Next Generation Vaccine Adjuvants Workshop - Constellation A

2pm: Chair opening remarks: Rebecca Kurnat M.S., Head of Product, SaponiQx

Presentations: 2.10pm – 4.00pm:

Using synthetic biology in adjuvant technology & creating a pipeline of vaccine adjuvants

Dr John Baldoni, Head of Science, SaponiQx

Next generation TLR agonists & RIG-I as adjuvants

Dr Steve Reed, CEO, HDT Bio

An oral adjuvant to augment vaccine effectiveness

Dr Upendra Marathi, President & CEO, 7Hills Pharma

Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation

Dr Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research, LaJolla Institute for Immunology

4.00-5:00pm Q&A and Panel Discussion with all speakers

  • What are the limitations of current adjuvants?
  • Importance of unique formulations & combination adjuvants
    • Kinetics, localization, dose sparing
  • Ensuring a secure supply of known adjuvants
    • Rapid response and stockpiling
  • Emerging concepts in adjuvant science
  • What mechanisms are required to advance vaccines?
  • Novel adjuvant technology – synthetic adjuvants
  • Development of an adjuvant pipeline – can new adjuvants rescue previously failed vaccines?
  • What factors drive clinical failure?
Nov 2814:00
Conference pass

Workshop B [Room: Constellation B]

WAC - Antibody Drug Discovery For Infectious Disease Workshop - Constellation B

Antibody Drug Discovery for Infectious Diseases

2pm – 5pm

2pm: Chair opening remarks:Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

Presentations 2.10pm – 4pm:

Shark-derived nanobodies for diagnostic and therapeutic use

Dr Helen Dooley, Assistant Professor, University of Maryland School of Medicine

Developing high affinity, high avidity, IgM antibodies for the prevention and treatment of infectious diseases

Dr Sha Ha, VP, CMC, IGM Biosciences

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

Dr Shivshankar “Shankar” Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus

Dr Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research

La Jolla Institute for Immunology, LaJolla Institute

Tackling viral infections by human monoclonal antibodies

Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

4.00-5:00pm Panel & Q&A with speakers: Overcoming hurdles in antibodies discovery and development against viral infection

  • How to develop antibodies that are resistant to viral mutations?
  • How can the cost be justified if other therapeutics are available?
  • What effects has the pandemic had in increasing desire for therapeutic antibodies
  • The role of FC and FC modifications to enhance effector function

Create your personal agenda –check the favourite icon

Nov 298:30
Conference pass

Opening keynote presentation: Integrated Pandemic Preparedness

WVIC - Plenary - Constellation A&B
  • How vaccines, monoclonals, direct acting antiviral, agents targeting host factors have essential roles in mounting a broad, response to future pandemics
  • The need to develop and validate assays for detection of infection and measurement of immunity
Nov 299:00
Conference pass

Panel: HIV – how can we end the epidemic?

WVIC - Plenary - Constellation A&B
    li>
  • How is new research bringing the goal of a cure within reach?

  • HIV Vaccine, antibody, and antiviral landscape

  • Merits / potential of different approaches – mRNA, bNAbs, LAAV, pre-exposure prophylaxis, prophylactic vs therapeutic vaccines

    o How are we defining functional cure?

    o Is the benchmark for a vaccine too high given the effectiveness of LAAV regimen?

  • To achieve success must reach all those disproportionately affected - How can PPP help to achieve this?

Nov 2910:00
Conference pass

Defining immune health and its implications for ID & Cancer

WVIC - Plenary - Constellation A&B
  • How do we define immune fitness / immune health – progress towards human immunome
  • How are we studying this at a systems level? How do vaccines positively impact immune fitness?
  • Defining tumor archetypes – what common immunological features contribute to better response rates
Nov 2911:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 2911:45
Conference pass

How can we utilize mRNA technology to develop next generation therapeutics?

Interactive Roundtables
Ariel Weinberger, Chief Executive Officer, Autonomous Therapeutics
Nov 2911:45
Conference pass

How to effectively tailor prevention and treatment strategies to pediatric populations?

Interactive Roundtables
Nov 2911:45
Conference pass

The future of vaccine trial sites post-COVID

Interactive Roundtables
Nov 2912:30
Conference pass

Exhibition & Partnering Break

Keynotes
  • Lunch served in exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 2913:45
Conference pass
Nov 2913:45
Conference pass

Chair’s opening remarks

WVIC - Immune Profiling & Technology - Constellation B
Nov 2913:45
Conference pass

Chair’s opening remarks

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2913:45
Conference pass
Nov 2913:45
Conference pass
Nov 2913:50
Conference pass

Oral COVID-19 vaccine ph II trials

WVIC - ID Vaccines - Constellation A
Nov 2913:50
Conference pass

Panel: Understanding the TME; what’s left to learn?

WVIC - Immune Profiling & Technology - Constellation B
  • How can we apply proteomics to the TME – how is this informing multiple targets?
  • Balancing power of profiling and proteomics – will proteomics ever be ready for plug and play in the clinic?
  • Advances in imaging the TME
  • Characterizing effective T cell responses in and that track to the TME
  • Non-tumor components of the TME as a therapeutic strategy -stromal cells, myeloid cells, other tissue resident cells
Nov 2913:50
Conference pass

Galinpepimut-S: Clinical development of a WT1-targeting multivalent heteroclitic epitope immunotherapeutic

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2913:50
Conference pass

Visualizing vaccine-induced on- and off-target antibody responses to HIV Env using electron microscopy

WAC - HIV - Commodore A
Nov 2913:50
Conference pass

The Centers for Research in Emerging Infectious Diseases (CREID) Network: Research Integrated Surveillance and Monitoring

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2914:20
Conference pass

PTX-COVID19-B mRNA Vaccine: Phase 2 Immunobridging Study vs. Comirnaty® Topline Results

WVIC - ID Vaccines - Constellation A
Nov 2914:20
Conference pass

Updates in the clinical development of therapeutic glioblastoma vaccine, VBI-1901

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2914:20
Conference pass

Kick and kill approach to HIV treatment

WAC - HIV - Commodore A
Nov 2914:20
Conference pass

Applying machine learning for antiviral drug discovery

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2914:50
Conference pass

SARS-CoV-2 Vaccine design to broaden effector immune responses

WVIC - ID Vaccines - Constellation A
Nov 2914:50
Conference pass

Progress of therapies to overcome suppression in the TME

WVIC - Immune Profiling & Technology - Constellation B
Nov 2914:50
Conference pass

A new approach to therapeutic cancer vaccines

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2914:50
Conference pass

Using nanocrystal prodrugs as ultra-long-acting chemical treatment for HIV

WAC - HIV - Commodore A
Dr Howard Gendelman, Co-founder, Exavir Therapeutics
Nov 2914:50
Conference pass

Development of broad-spectrum protease inhibitors to combat emerging viral diseases

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2915:20
Conference pass

A new vaccine platform for emerging virus threats such as SARS-2, HIV, and RSV

WVIC - ID Vaccines - Constellation A
Nov 2915:20
Conference pass

FortiVac APC-targeted vaccine for powerful CD8+ T cell responses

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2915:20
Conference pass

Glycoconjugate approaches for evoking antibodies to sugars on HIV-1

WAC - HIV - Commodore A
Nov 2915:20
Conference pass

Fleximers - a strategic approach to broad spectrum antiviral therapeutics

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2915:35
Conference pass

Preclinical evaluation of a low-dose universal SARS-CoV-2 mRNA vaccine

WVIC - ID Vaccines - Constellation A
Nov 2915:50
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 2916:20
Conference pass

Vaccine trial storage and distribution challenges

WVIC - ID Vaccines - Constellation A
Nov 2916:20
Conference pass

Mapping immune profiles to improve clinical outcomes in oncology

WVIC - Immune Profiling & Technology - Constellation B
Nov 2916:20
Conference pass

Novel Checkpoint Inhibitor Combination Vaccines (PD-1, PD-L1, CTLA-4, TIGIT, LAG3)

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2916:20
Conference pass

Confronting the access challenges for HIV prevention: a law and policy perspective

WAC - HIV - Commodore A
Nov 2916:20
Conference pass

Tackling multiple Marburg virus strains with humanized mAbs

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2916:50
Conference pass

Improving clinical trial recruitment

WVIC - ID Vaccines - Constellation A
Nov 2916:50
Conference pass

A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment

WVIC - Immune Profiling & Technology - Constellation B
Nov 2916:50
Conference pass

Versamune t-cell activating platform for HPV related cancers

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2916:50
Conference pass

Are long-acting ARTs the future of HIV prevention and treatment?

WAC - HIV - Commodore A
  • How can we improve the half-life of long-acting ARTs?
  • How can we enhance the uptake/usage of long-acting formulations?
  • What are the implementation challenges for therapies?
  • What are the key policy issues for these types of therapies?
  • Why can long-acting injectable therapies be difficult to access in LMIC?
Nov 2916:50
Conference pass

A repurposing antiviral solution for the prevention and treatment of Dengue

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2917:05
Conference pass

How Benchmark Research used an innovative real-time data capture tool to reduce protocol deviations by 40% on vaccine trials

WVIC - ID Vaccines - Constellation A
Eric Elander, Director Business Development, Clinical Research IO (CRIO)
Nov 2917:20
Conference pass

Studies informing mechanisms of resistance in oncology

WVIC - Immune Profiling & Technology - Constellation B
Nov 2917:20
Conference pass

7HP349, an integrin agonist to overcome resistance to immune checkpoint blockade

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 2917:20
Conference pass

Structural mapping of the humoral immune response to the Lassa virus glycoprotein

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2917:35
Conference pass

Establishment of a high-throughput screening platform for antivirals: Zika Protease

WAC - Emerging & Reemerging Diseases - Commodore B
Nov 2917:50
Conference pass

Evening Networking Drinks Reception, come to the beautiful hotel terrace (outside)

Evening Networking Drinks

Sponsored by Headlands Research

Create your personal agenda –check the favourite icon

Nov 308:50
Conference pass

Chair’s opening remarks: The Antiviral Program for Pandemics (APP) and key support mechanisms available

WAC - Plenary - Commodore A&B
Nov 309:00
Conference pass

Global Health Goals – can we get back on track?

WVIC - Plenary - Constellation A&B
  • How has the pandemic affected the status of the epidemics of tuberculosis, malaria and neglected tropical diseases?
  • Silver linings – new investments in immunization infrastructure – understanding of barriers and opportunities in promoting vaccination within communities and countries. How do we try to capitalize on some of the new pathways generated because of covid?
  • How will malaria vaccines be implemented? How does this vaccine need to be promoted differently to previous vaccines? How to communicate value of vaccines in burdened communities. Integrated strategy required.
  • TB vaccines how are we moving forward? Next steps for TB vaccines.
Nov 309:10
Conference pass

Panel: What is the future of COVID-19 therapeutics?

WAC - Plenary - Commodore A&B
  • What are the key areas of focus for 2023 and onwards?
  • What novel therapies are being investigated?
  • Is there a particular part of the SARS-CoV-2 infection cycle being targeted?
  • Is there a silver bullet out there and what would it look like?
  • How to ensure therapeutic interventions are easily accessible?
  • How will the current and future COVID-19 therapeutics be used in the case of a new outbreak?
Nov 3010:00
Conference pass

Challenges & opportunities in moving immuno-oncology drugs into earlier lines of therapy

WVIC - Plenary - Constellation A&B
  • What are the challenges that need to be overcome before we can move immunotherapies into earlier stages?
  • What is effect of moving earlier in moving into adjuvant/neoadjuvant space? The need to understand progression much earlier in disease.
  • What are our current assumptions – what data do we need to pressure test them? How do we collect data? What data do we need?
Nov 3010:00
Conference pass

Panel: Overcoming obstacles in developing therapeutics for neglected and emerging diseases

WAC - Plenary - Commodore A&B
  • What are the challenges in designing effective clinical trials for these diseases?
  • What role do platform trials play?
  • What are the key regulatory issues?
  • How would a collaborative nature between researchers and regulatory help with development?
  • Why is funding an issue? What can be done to combat this issue?
  • How to react most efficiently to unexpected disease surges (e.g Monkeypox outbreak)
Nathalie Strub-Wourgaft, COVID-19 Response & Pandemic Preparedness Director,, Drugs for Neglected Diseases initiative-DNDi
Dr Phil Gomez, Chief Executive Officer, SIGA Technologies, Inc.
Mara Kreishman-Deitrick, Deputy Commander, United States Army Medical Material Development Activity
Nov 3011:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 3011:30
Conference pass

Chair’s opening remarks

WVIC - Immune Profiling & Technology - Constellation B
Nov 3011:30
Conference pass

Chair’s opening remarks

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3011:30
Conference pass
Nov 3011:30
Conference pass

Chair’s opening remarks

WAC - Delivery & Technology - Commodore B
Nov 3011:40
Conference pass

Panel: Research & development goals for influenza vaccines

WVIC - ID Vaccines - Constellation A
  • What is the status of the influenza vaccine R&D landscape?
  • What areas of R&D are we focusing on to improve influenza vaccines?
  • Strategic goals for seasonal vs universal flu vaccines
  • Recent milestones achieved and gaps to address
  • What tools do we need to inform policy, and preparedness planning?
  • Pivoting to new manufacturing platforms to ensure faster response – what are the challenges
Nov 3011:40
Conference pass

Recent studies informing our understanding of SARS-CoV-2 Immunity

WVIC - Immune Profiling & Technology - Constellation B
Nov 3011:40
Conference pass

PIONEER – development of patient specific cancer immunotherapies

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3011:40
Conference pass

Pegylated interferon lambda—a single dose treatment for COVID

WAC - COVID-19 - Commodore A
Nov 3011:40
Conference pass

Innovative antiviral drug discovery software – Case study COVID Moonshot

WAC - Delivery & Technology - Commodore B
Nov 3012:10
Conference pass

A CRO harnessing a multi-faceted diagnostic approach to support a Moderna SARS-COV-2 Phase 3 vaccine trial

WVIC - Immune Profiling & Technology - Constellation B
Nov 3012:10
Conference pass

Stem cell-based platforms for delivery and potentiation of oncolytic viruses

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3012:10
Conference pass

Structure-based drug design against SARS-CoV-2 main protease using X-rays, neutrons and computation

WAC - COVID-19 - Commodore A
Nov 3012:10
Conference pass

AI driven automated viral infectivity assay to expedite antiviral drug discovery

WAC - Delivery & Technology - Commodore B
Nov 3012:25
Conference pass

SERA identifies antibody epitopes induced by Moderna vaccines and boosters

WVIC - Immune Profiling & Technology - Constellation B
Nov 3012:40
Conference pass

Development of mosaic nanoparticle vaccines to elicit broadly protective antibody responses

WVIC - ID Vaccines - Constellation A
Nov 3012:40
Conference pass

Rapid detection of neutralizing antibodies and resistant viruses that escape antibody recognition

WVIC - Immune Profiling & Technology - Constellation B
Nov 3012:40
Conference pass

Individualized Neoantigen Immunotherapy in early stage and advanced solid tumors

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3012:40
Conference pass

Development of fully human monoclonal antibodies against SARS-CoV2 using peripheral B-cells from COVID-19 survivors

WAC - COVID-19 - Commodore A
Nov 3012:40
Conference pass

Pathological modeling and control system for optimizing antivirals for COVID-19 and beyond

WAC - Delivery & Technology - Commodore B
Nov 3013:10
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 3014:30
Conference pass

Infectimmune platform for univerval flu vaccine development

WVIC - ID Vaccines - Constellation A
Siva Gandhapudi, Director, Immunology Operations, P.D.S. Biotechnology Corp
Nov 3014:30
Conference pass

Development of custom assays to measure vaccine efficacy

WVIC - Immune Profiling & Technology - Constellation B
Nov 3014:30
Conference pass

Personal dendritic cell vaccines for cancer and covid-19

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3014:30
Conference pass

Showcase 1: Driven by personal experience: Discovery and development of broad-spectrum antiviral agents against respiratory track viruses

WAC - COVID-19 - Commodore A
Nov 3014:30
Conference pass

Vaccine and Treatment Efficacy: viral disease, patient illness perception and implications for respiratory viral challenge studies

WAC - Delivery & Technology - Commodore B
Nov 3014:45
Conference pass

Novel FluoroSpot assay to detect rare Memory B cells and their role in P.falciparum malaria

WVIC - Immune Profiling & Technology - Constellation B
Nov 3014:45
Conference pass

Showcase 2: Zapnometinib: a broad-spectrum antiviral for Covid-19, Influenza and other viral diseases with pandemic potential

WAC - COVID-19 - Commodore A
Nov 3015:00
Conference pass

LUNAR – Flu & Covid-19 Vaccines

WVIC - ID Vaccines - Constellation A
Sean Sullivan, Executive Director, Head of Technology Innovation, Arcturus Therapeutics
Nov 3015:00
Conference pass

Pre-clinical evaluation of HIV envelope glycoprotein vaccine candidates towards the clinic

WVIC - Immune Profiling & Technology - Constellation B
Nov 3015:00
Conference pass

CARG-2020, an oncolytic and immunotherapy self-amplifying mRNA vector for treatment of solid tumors, prevents tumor recurrence

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3015:00
Conference pass

Showcase 3: Ensitrelvir, a novel 3C-like protease inhibitor for once daily oral treatment of mild-to-moderate COVID-19

WAC - COVID-19 - Commodore A
Nov 3015:00
Conference pass

Targeted Protein Degradation–A novel approach to combat viral pathogens

WAC - Delivery & Technology - Commodore B
Dr Priscilla Yang, Professor, Stanford University School of Medicine (USA)
Nov 3015:15
Conference pass

Showcase 4: Broad spectrum inhibitors against viral methyltransferases

WAC - COVID-19 - Commodore A
Nov 3015:30
Conference pass

Codon-deoptimized live attenuated vaccines for respiratory pathogens

WVIC - ID Vaccines - Constellation A
Nov 3015:30
Conference pass

Intensified, low-cost manufacturing of viral vectors and viral vaccines using HIP-Vax technology

WVIC - Immune Profiling & Technology - Constellation B
Nov 3015:30
Conference pass

Showcase 5: Broadly acting cathepsins inhibitor against omicron and other variants of concern

WAC - COVID-19 - Commodore A
Nov 3015:30
Conference pass

Inhaled Interferon-beta (SNG001) for the treatment of COVID-19 and other severe viral lung infections

WAC - Delivery & Technology - Commodore B
Phillip Monk, CSO, Synairgen Research Ltd
Nov 3015:45
Conference pass

From sequence to manufacturable spike proteins for vaccine development

WVIC - Immune Profiling & Technology - Constellation B
Nov 3015:45
Conference pass

Showcase 6: Mechanism based designed 3CL inhibitors. From HRV to Covid19

WAC - COVID-19 - Commodore A
Nov 3016:00
Conference pass

Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Nov 3016:30
Conference pass

Developing broad-spectrum influenza vaccines against pandemic threats

WVIC - ID Vaccines - Constellation A
Nov 3016:30
Conference pass

Intranasal Immunization: Device and Formulation Promises and Challenges

WVIC - Immune Profiling & Technology - Constellation B
Nov 3016:30
Conference pass

Developing oral tissue-targeted TLR7 agonists for cancer immunotherapy

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3016:30
Conference pass

Treating COVID-19 in Pregnancy – The COVID-19 International Drug Pregnancy Registry (COVID-PR)

WAC - COVID-19 - Commodore A
Nov 3016:30
Conference pass

A Pan-Coronavirus + Pan-Influenza Therapeutic: One Drug for Many Bugs to Address Future Pandemics

WAC - Delivery & Technology - Commodore B
Nov 3017:00
Conference pass

Molecular and immunogenetic definitions of broadly conserved influenza vaccine epitopes

WVIC - ID Vaccines - Constellation A
Nov 3017:00
Conference pass

How broadly neutralizing antibodies guide the design of pan-beta coronavirus vaccines

WVIC - Immune Profiling & Technology - Constellation B
Nov 3017:00
Conference pass

Developing engineered IgM antibodies for cancer

WVIC - Cancer Immunotherapy - Britannia/Cambria
Nov 3017:00
Conference pass

Pandemic Antiviral Discovery (PAD) initiative–Catalysing antiviral discovery and development

WAC - COVID-19 - Commodore A
Nov 3017:00
Conference pass

Cellular Nanosponges as an Emerging Antiviral Technology

WAC - Delivery & Technology - Commodore B
Nov 3017:30
Conference pass

End of conference sessions, please make your way to the entrance for coaches to our off-site networking drinks

Keynotes

Please make your way to the entrance for coaches to our off-site networking drinks at Stone Brewery

Nov 3018:00
Conference pass

Coaches to Off-site Networking Drinks Reception - Stone Brewery

Evening Networking Drinks

Please make your way to the entrance for coaches to our off-site networking drinks at Stone Brewery

Create your personal agenda –check the favourite icon

Dec 18:20
Conference pass

Chair’s opening remarks

WVIC - Plenary - Constellation A&B
Dec 18:20
Conference pass
Dec 18:30
Conference pass

Accelerating innovation –leveraging partnerships and collaborations to advance solutions to ID & Cancer

WVIC - Plenary - Constellation A&B
  • What are the advantages of partnering with big pharma, federal labs, accelerators, foundations and private investors?
  • What are their programmatic interests of the players involved in getting technologies to market?
  • What emerging technologies are those in charge of partnering and collaboration most excited about?
  • How can you position yourself optimally to get your tech noticed?
Dec 18:30
Conference pass

Panel: Therapeutic approaches to pandemic preparedness

WAC - Plenary - Commodore A&B
  • Prediction–Predicting the next viral threat and developing a drug with a specific target
  • Broad-spectrum–Developing drugs that work broadly across many stains/viruses
  • Platforms–Warp speed platforms to develop therapeutics once a threat appears
  • What are the advantages and disadvantages of each approach?
Dec 19:30
Conference pass

BRUNCH - Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Dec 110:00
Conference pass

Chair’s opening remarks

WVIC - ID Vaccines - Constellation A
Dec 110:00
Conference pass

Chair’s opening remarks

WVIC - New Technology & Partnerships - Constellation B
Dec 110:00
Conference pass

Chair’s opening remarks

WAC - Respiratory Viruses - Commodore A
Dec 110:00
Conference pass

Chair’s opening remarks

WAC - Hepatitis - Commodore B
Dec 110:10
Conference pass
Dec 110:10
Conference pass

How can an Intellectual Property International Consortium (IPIC) benefit small biotechs?

WVIC - New Technology & Partnerships - Constellation B
Dec 110:10
Conference pass

Developing immune cell ligands as a treatment strategy for influenza

WAC - Respiratory Viruses - Commodore A
Imrul Shahriar, Scientist, Eradivir Therapeutics; Graduate Research Assistant & PhD Candidate, Purdue Unviersity
Dec 110:10
Conference pass

New and Emerging Strategies for the Treatment and Potential Cure of Hepatitis B Virus and Hepatitis D Virus Infections

WAC - Hepatitis - Commodore B
Dec 110:25
Conference pass

How are investors thinking about biopharma stocks?

WVIC - New Technology & Partnerships - Constellation B
Dec 110:40
Conference pass

Bacterial structural vaccinology and novel target delivery

WVIC - ID Vaccines - Constellation A
Dec 110:40
Conference pass

Showcase 1: Early development of Smallpox & Monkey Pox Vaccines

WVIC - New Technology & Partnerships - Constellation B
Dec 110:40
Conference pass

Novel broad-spectrum influenza A PB2 inhibitor: clinical update

WAC - Respiratory Viruses - Commodore A
Dec 110:40
Conference pass

Subviral particle clearance and transaminase flares – roles in functional cure

WAC - Hepatitis - Commodore B
Dec 110:55
Conference pass

A Combinatorial Live Attenuated Vaccine Strategy Against Pneumonia and Otitis Media

WVIC - ID Vaccines - Constellation A
Dec 111:10
Conference pass

B-Tech vector platform for development of next gen Pertussis and TB vaccines

WVIC - ID Vaccines - Constellation A
Dec 111:10
Conference pass

Showcase 2: A new class of RNA for pan-variant immunity

WVIC - New Technology & Partnerships - Constellation B
Ariel Weinberger, Chief Executive Officer, Autonomous Therapeutics
Dec 111:10
Conference pass

The role of influenza antivirals–How can we reduce morbidity and mortality at the individual and population level?

WAC - Respiratory Viruses - Commodore A
Dec 111:30
Conference pass

BRUNCH - Exhibition & Partnering Break

Keynotes
  • Tea, Coffee and Refreshments served in the exhibition area
  • One-to-one networking meetings, Poster Presentations
Dec 112:30
Conference pass

Vaxchora® (Cholera Vaccine, Live, Oral) – An Overview

WVIC - ID Vaccines - Constellation A
Dec 112:30
Conference pass

Showcase 3: Engineering a novel SARS-CoV2 B-cell epitope vaccine and investigation in transgenic K18-hACE2 mice

WVIC - New Technology & Partnerships - Constellation B
Dec 112:30
Conference pass

Development of CARG-201, a self-amplifying mRNA vector, for immunotherapy of chronic hepatitis B

WAC - Hepatitis - Commodore B
Dec 113:00
Conference pass

Neutralizing Staphylococcus aureus virulence for vaccination and immunotherapy

WVIC - ID Vaccines - Constellation A
Dec 113:00
Conference pass

Showcase 4: PLACCINE Nucleic Acid Vaccine Platform – Preclinical POC using a SARS-CoV-2 pDNA construct

WVIC - New Technology & Partnerships - Constellation B
Dec 113:00
Conference pass

Lonafarnib—first oral antiviral for Hepatitis D

WAC - Hepatitis - Commodore B
Dec 113:40
Conference pass

Joint Closing Keynote Plenary Session Opening Remarks

WVIC - Plenary - Constellation A&B
Dec 113:45
Conference pass

Keynote Presentation of the Upcoming Film: SHOT IN THE ARM

WVIC - Plenary - Constellation A&B

Please join us for a special sneak peek and a keynote discussion of SHOT IN THE ARM, the new documentary from Academy Award nominated director Scott Hamilton Kennedy. Through the lens of the COVID-19 pandemic, and the vantage point of top medical experts (featuring Paul Offit, Peter Hotez and Tony Fauci) and anti-vaccine activists (featuring Robert Kennedy, jr., Andrew Wakefield and Del Bigtree), the film explores how difficult it is for the public to make the best decisions in the face of overwhelming distrust and disinformation. As well as how empathy and understanding of reasons behind vaccine hesitancy are powerful tools to help restore confidence and faith in public health and the social contract to protect our communities.

last published: 01/Dec/22 17:25 GMT

For conference programme and speaking opportunities:
Lauren Sheppard

lauren.sheppard@terrapinn.com

For sponsorship and exhibition opportunities:
Thomas Hall

thomas.hall@terrapinn.com